Can-Fite Reports Data from its Partner Vetbiolix’s Clinical Study of Piclidenoson in Dogs with Osteoarthritis
Shots:
- Can-Fite BioPharma reported data from Vetbiolix's osteoarthritis study in dogs treated with piclidenoson (100μg/kg & 500μg/kg, oral, BID) for 90 days with 1EP of symptom severity evaluation using the LOAD questionnaire & 2EP of pain evaluation using VAS by pet parents & NRS by veterinarians for lameness & pain
- The study met its 1EP & 2EP, showing dose & time dependent inhibitory action of piclidenoson on LOAD, VAS & NRS plus improved clinical status & reduced pain with 500µg/kg dose
- Based on these results, Vetbiolix can now opt for a full license agreement (signed in Jun 2021) with Can-Fite under which the former will pay upfront, milestones & sales-based royalties on regulatory approval
Ref: Can-Fite | Image: Can-Fite
Related News:- Merck Animal Health’s Innovax-ND-H5 Vaccine Gains the EC’s Marketing Authorization for Chickens
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
